Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients

Tehran University of Medical Sciences

Status

Completed

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: Pioglitazone

Drug: Metformin

Study type

Interventional

Funder types

Other

Identifiers

NCT01593371

90-D-130-655

Details and patient eligibility

About

Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin), are two major groups of hypoglycemic medications that while function via different pathways, are both effective in short- and long-term glycemic control . These medications diminish or at least delay long term micro- and macrovascular complications associated with prolonged insulin resistance although at different rates. The mechanisms by which this aim is achieved, nevertheless, remains largely unclear. With adipokines playing a key role in development of both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these substances by direct and indirect routes.

Enrollment

98 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria (2011) for diagnosis of diabetes

Exclusion criteria

previous intake of oral hypoglycemic agents for treatment of diabetes or other hyperglycemia associated conditions
intake of glucocorticoids in the past one year
major illnesses of heart, lung, kidney, and liver.